Scarica l'app Stockscreener
1.63
7.47%
-0.11
Dopo l'orario di chiusura:
1.66
0.03
+1.84%
Precedente Chiudi:
$1.74
Aprire:
$1.72
Volume 24 ore:
2.18M
Relative Volume:
3.12
Capitalizzazione di mercato:
$92.79M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.1727
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
-21.08%
1M Prestazione:
-18.69%
6M Prestazione:
+11.03%
1 anno Prestazione:
-24.41%
Intervallo 1D:
$1.50
$1.786
Intervallo di 1 settimana:
$1.50
$2.06
Portata 52W:
$1.12
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.63 | 92.79M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - StockTitan
Hemogenyx Pharmaceuticals marks major milestone with first patient dosing - Proactive Investors UK
Milestone Pharmaceuticals Prepares for CARDAMYST Launch - TipRanks
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray - Marketscreener.com
Milestone Pharmaceuticals secures key patent for CARDAMYST By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals secures key patent for CARDAMYST - Investing.com India
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil - The Manila Times
Patent Victory: How Milestone's CARDAMYST Just Gained 6 Extra Years of Market Exclusivity - StockTitan
Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9% - MarketBeat
Adversity is less terrifying than hope: Milestone Pharmaceuticals Inc (MIST) - SETE News
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
MISTMilestone Pharmaceuticals Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - Yahoo Finance
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 - The Manila Times
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - StockTitan
Retail investors who hold 57% of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) gained 14%, institutions profited as well - Simply Wall St
Milestone Pharmaceuticals Inc (MIST) may enjoy gains as insiders got busy in the recent days - Knox Daily
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - The News Heater
Milestone Pharmaceuticals Inc (MIST) Stock: A Year of Highs and Lows - The InvestChronicle
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
BlackRock, Inc. Reduces Stake in Milestone Pharmaceuticals Inc - GuruFocus.com
The Top 7 Biopharma Licensing Deals of 2024 - BioSpace
What was Milestone Pharmaceuticals Inc (MIST)’s performance in the last session? - US Post News
Insider’s View: Deciphering Fangdd Network Group Ltd (DUO)’s Financial Health Through Ratios - The Dwinnex
Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term - Yahoo Finance
What is HC Wainwright's Forecast for MIST FY2029 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MIST - MarketBeat
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Insights
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research - BioPharma Dive
HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings - Defense World
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone - PR Newswire
Milestone Pharma Faces FDA Decision In MarchWill It Mean Heartbreak Or Happiness For Investors? - RTTNews
FY2029 Earnings Estimate for MIST Issued By HC Wainwright - Defense World
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones - ACCESS Newswire
Milestone gears up for CARDAMYST launch in 2025 By Investing.com - Investing.com Australia
Milestone gears up for CARDAMYST launch in 2025 - Investing.com
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC - The Manila Times
Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright maintains $25 target on Milestone shares - MSN
HC Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential - ACCESS Newswire
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - ACCESS Newswire
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Medexus Secures FDA Approval for GRAFAPEX, Eyes $100M Revenue Milestone - TipRanks
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - The Manila Times
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.95%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):